When 16-year-old Gianna Cirella, an athlete at Toll Gate High School, was sick in the hospital a year ago with a blood infection, she needed a lot of units of ...
Feeds
12069 items (12069 unread) in 74 feeds
Acinar Cell Carcinoma
(147 unread)
Acinic Cell Carcinoma
(64 unread)
Adenoid Cystic Carcinoma
(252 unread)
Adrenal Gland Cancer
(984 unread)
Ampulla Of Vater
(146 unread)
Anal Cancer
(1163 unread)
Angiosarcoma
(273 unread)
Appendix Cancer
(239 unread)
Bile Duct Cancer
(1442 unread)
Brain and CNS
(1693 unread)
Carcinoid
(353 unread)
Endocrine/Neuroendocrine
(1290 unread)
Gall Bladder Cancer
(377 unread)
Hemangioendothelioma
(159 unread)
Hepatoblastoma
(231 unread)
Pancreas
(203 unread)
Phyllodes
(171 unread)
PMP and Mucinous Tumors
(152 unread)
Rhabdomyosarcoma
(375 unread)
Sarcoma
(2355 unread)
Google - Angiosarcoma (100 unread)
1
2
-
Health Check: Blood donors needed at NBC 10 Holiday Blood Drive - Turn to 10
Posted: December 15th, 2018, 11:09pm GMT
Health Check: Blood donors needed at NBC 10 Holiday Blood Drive Turn to 10 -
TRACON Pharmaceuticals (TCON) Hits New 1-Year Low at $1.03 - Modern Readers
Posted: December 14th, 2018, 12:49am GMT
TRACON Pharmaceuticals (TCON) Hits New 1-Year Low at $1.03 Modern ReadersShares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) hit a new 52-week low during trading on Thursday . The company traded as low as $1.03 and last ...
-
Angiosarcomas Treatment Market Business Opportunties and Growth 2018 to 2026 - Morgan Newspaper USA
Posted: December 14th, 2018, 10:19pm GMT
Angiosarcomas Treatment Market Business Opportunties and Growth 2018 to 2026 Morgan Newspaper USAThe business research report on “Angiosarcomas Treatment Market” Research Report 2018- 2026 covers summery, market outlook, trends, classification, value ...
-
Angiosarcomas Treatment Market Research Study including Growth Factors, Types and Application by regions from 2018 to 2026 - Coherent Wire
Posted: December 13th, 2018, 9:51am GMT
Angiosarcomas Treatment Market Research Study including Growth Factors, Types and Application by regions from 2018 to 2026 Coherent WireThe report presents an introductory as well as detailed information about the Angiosarcomas Treatment Market through a well-organized layout divided into easy ...
-
Angiosarcomas Treatment Market To Grow Like Never Before By 2026 - The Industry Chronicle
Posted: December 12th, 2018, 2:16pm GMT
Angiosarcomas Treatment Market To Grow Like Never Before By 2026 The Industry ChronicleThe Angiosarcomas Treatment Market covers the present scenario (with the base year being 2018) and the growth prospects of global Angiosarcomas ...
-
Young Nebraska basketball fan battling cancer receives a Magic Moment - KLKN
Posted: December 11th, 2018, 8:56pm GMT
Young Nebraska basketball fan battling cancer receives a Magic Moment KLKNA young Nebraska basketball fan who is battling cancer gets a wonderful surprise when he receives a Magic Moment, sponsored by Union Bank.
-
Orphan Drugs Market Research Report Focusing on Leading Fortune Companies "AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche, GlaxoSmithKline plc, & Others" - openPR
Posted: December 11th, 2018, 11:48am GMT
Orphan Drugs Market Research Report Focusing on Leading Fortune Companies "AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche, GlaxoSmithKline plc, & Others" openPRGlobal Orphan Drugs Market is expected to garner $169 billion from $106 billion and register a CAGR of 6.8% during the forecast period, 2016-2022. Orphan ...
-
Keating Investment Counselors Lowered Disney Walt Co (DIS) Holding; Athenex (ATNX) Shorts Down By 3.81% - D Minute
Posted: December 11th, 2018, 11:42am GMT
Keating Investment Counselors Lowered Disney Walt Co (DIS) Holding; Athenex (ATNX) Shorts Down By 3.81% D MinuteKeating Investment Counselors Inc decreased Disney Walt Co (DIS) stake by 8.07% reported in 2018Q3 SEC filing. Keating Investment Counselors Inc sold ...
-
TRACON Pharmaceuticals Inc (TCON) Stake Raised by Bridgeway Capital Management Inc. - Fairfield Current
Posted: December 11th, 2018, 10:15am GMT
TRACON Pharmaceuticals Inc (TCON) Stake Raised by Bridgeway Capital Management Inc. Fairfield CurrentBridgeway Capital Management Inc. grew its position in TRACON Pharmaceuticals Inc (NASDAQ:TCON) by 100.0% during the 3rd quarter, according to its most ...
-
Angiosarcomas Treatment Market Key Players, Share, Trend, Applications, and Segmentation - Coherent News
Posted: December 10th, 2018, 1:11am GMT
Angiosarcomas Treatment Market Key Players, Share, Trend, Applications, and Segmentation Coherent NewsAngiosarcomas Treatment Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a ...
-
Orphan Drugs Market Report 2018:2026 – Industry Growth Forecasts by Manufacturers, Countries, Type and Application - Coherent News
Posted: December 10th, 2018, 1:11am GMT
Orphan Drugs Market Report 2018:2026 – Industry Growth Forecasts by Manufacturers, Countries, Type and Application Coherent NewsOrphan Drugs Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a valuable source of ...
-
Intrauterine Contraceptive Devices Market Will Play Crucial Role For Various Industries Growth In Near Future!! - Coherent News
Posted: December 10th, 2018, 1:11am GMT
Intrauterine Contraceptive Devices Market Will Play Crucial Role For Various Industries Growth In Near Future!! Coherent NewsIntrauterine Contraceptive Devices Market report is a research database spread across various pages with multiple tables and figures in it. The research covers ...
-
Magnetic Resonance Imaging (MRI) Systems Market 2018-2026 Analysis by Regional Development Status, Market Size, Market Dynamics, Applications - Coherent News
Posted: December 10th, 2018, 1:11am GMT
Magnetic Resonance Imaging (MRI) Systems Market 2018-2026 Analysis by Regional Development Status, Market Size, Market Dynamics, Applications Coherent NewsMagnetic Resonance Imaging (MRI) Systems Market report is a research database spread across various pages with multiple tables and figures in it.
-
Pharmaceutical Filters Market Expoler Future Growth With Top Key Players - Coherent News
Posted: December 10th, 2018, 12:55am GMT
Pharmaceutical Filters Market Expoler Future Growth With Top Key Players Coherent NewsPharmaceutical Filters Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a valuable ...
-
Angiosarcomas Treatment Market – Global Industry – Key Players, Economic Impact, Cost and Revenue from 2018-2026 - Coherent Times
Posted: December 8th, 2018, 12:32am GMT
Angiosarcomas Treatment Market – Global Industry – Key Players, Economic Impact, Cost and Revenue from 2018-2026 Coherent TimesAngiosarcomas Treatment Market report offers a macroeconomic analysis with top company profiles, market share, product specifications, capacity and current ...
-
TRACON Pharmaceuticals (TCON) Lowered to Sell at Zacks Investment Research - BharataPress
Posted: December 7th, 2018, 3:10pm GMT
TRACON Pharmaceuticals (TCON) Lowered to Sell at Zacks Investment Research BharataPressTRACON Pharmaceuticals (NASDAQ:TCON) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on ...
-
Automotive Parts Remanufacturing Market Research Report To Design A Cohesive And Predictive Business Strategy - Coherent Wire
Posted: December 7th, 2018, 10:52am GMT
Automotive Parts Remanufacturing Market Research Report To Design A Cohesive And Predictive Business Strategy Coherent WireThe Automotive Parts Remanufacturing research report covers the current scenario and the growth prospects of the global Automotive Parts Remanufacturing ...
-
Brokers Set Expectations for TRACON Pharmaceuticals Inc’s FY2020 Earnings (TCON) - Fairfield Current
Posted: December 7th, 2018, 10:21pm GMT
Brokers Set Expectations for TRACON Pharmaceuticals Inc’s FY2020 Earnings (TCON) Fairfield CurrentTRACON Pharmaceuticals Inc (NASDAQ:TCON) – Jefferies Financial Group dropped their FY2020 EPS estimates for shares of TRACON Pharmaceuticals in a ...
-
Angiosarcomas Treatment Market to 2026- Strategies, Applications and Competitive Landscape - Coherent Chronicle
Posted: December 6th, 2018, 4:43am GMT
Angiosarcomas Treatment Market to 2026- Strategies, Applications and Competitive Landscape Coherent ChronicleAngiosarcomas Treatment Market report covers detailed competitive outlook including the market share and company profiles of the key participants operating in ...
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post FY2020 Earnings of $0.62 Per Share, Jefferies Financial Group Forecasts - Baseball Daily News
Posted: December 5th, 2018, 9:25pm GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post FY2020 Earnings of $0.62 Per Share, Jefferies Financial Group Forecasts Baseball Daily NewsTRACON Pharmaceuticals Inc (NASDAQ:TCON) – Analysts at Jefferies Financial Group decreased their FY2020 earnings per share estimates for TRACON ...
-
FY2020 Earnings Forecast for TRACON Pharmaceuticals Inc Issued By Jefferies Financial Group (NASDAQ:TCON) - PressOracle
Posted: December 4th, 2018, 9:21pm GMT
FY2020 Earnings Forecast for TRACON Pharmaceuticals Inc Issued By Jefferies Financial Group (NASDAQ:TCON) PressOracleTRACON Pharmaceuticals Inc (NASDAQ:TCON) – Investment analysts at Jefferies Financial Group cut their FY2020 EPS estimates for TRACON ...
-
Angiosarcomas Treatment Market Size, Share And Top Companies - Morgan Newspaper USA
Posted: December 4th, 2018, 6:56pm GMT
Angiosarcomas Treatment Market Size, Share And Top Companies Morgan Newspaper USAPublisher's Angiosarcomas Treatment market research report provides the newest industry data and industry future trends, allowing you to identify the products ...
-
Angiosarcomas Treatment Market Size, Share And Top Companies - Morgan Newspaper USA
Posted: December 4th, 2018, 6:56pm GMT
Angiosarcomas Treatment Market Size, Share And Top Companies Morgan Newspaper USAPublisher's Angiosarcomas Treatment market research report provides the newest industry data and industry future trends, allowing you to identify the products ...
-
Angiosarcomas Treatment Market Segmentation, Future Scope to 2026 With Top Companies - The Industry Chronicle
Posted: December 4th, 2018, 6:56am GMT
Angiosarcomas Treatment Market Segmentation, Future Scope to 2026 With Top Companies The Industry ChronicleThe Angiosarcomas Treatment Market research report is expected to have a highly positive outlook 2018-2026 according to CMI published a business reserch ...
-
'Santa Nate' embraces spirit of Christmas around Montgomery County - Houston Chronicle
Posted: December 3rd, 2018, 8:21pm GMT
'Santa Nate' embraces spirit of Christmas around Montgomery County Houston ChronicleNearly 20 years ago, while living and working in Montgomery County, a Conroe High School graduate made a reputation for himself by going a bit overboard ...
-
Sather Financial Group Boosted By $7.76 Million Its Starbucks (SBUX) Holding; Athenex (ATNX) Shorts Down By 5.9% - The FinExaminer
Posted: December 3rd, 2018, 5:51pm GMT
Sather Financial Group Boosted By $7.76 Million Its Starbucks (SBUX) Holding; Athenex (ATNX) Shorts Down By 5.9% The FinExaminerAthenex Inc (NASDAQ:ATNX) had a decrease of 5.9% in short interest. ATNX's SI was 3.57M shares in December as released by FINRA. Its down 5.9% from ...
-
New Long-Term Data on CALQUENCE Presented at ASH 2018 - Watertown Public Opinion
Posted: December 3rd, 2018, 4:45pm GMT
New Long-Term Data on CALQUENCE Presented at ASH 2018 Watertown Public OpinionWILMINGTON, Del.--(BUSINESS WIRE)--Dec 3, 2018--AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have ...
-
As Amicus Therapeutics (FOLD) Shares Declined, Shareholder Sectoral Asset Management Raised Its Position; As Open Text (OTEX) Stock Value Rose, Shareholder Thompson Siegel & Walmsley Has Trimmed by $36.59 Million Its Holding - The FinExaminer
Posted: December 3rd, 2018, 4:04pm GMT
As Amicus Therapeutics (FOLD) Shares Declined, Shareholder Sectoral Asset Management Raised Its Position; As Open Text (OTEX) Stock Value Rose, Shareholder Thompson Siegel & Walmsley Has Trimmed by $36.59 Million Its Holding The FinExaminerSectoral Asset Management Inc increased its stake in Amicus Therapeutics (FOLD) by 8.46% based on its latest 2018Q2 regulatory filing with the SEC. Sectoral ...
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Could Burn Your Long Portfolio After More Shorts - Thorold News
Posted: December 3rd, 2018, 2:11pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Could Burn Your Long Portfolio After More Shorts Thorold NewsThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 11.92% in short interest. TCON's total short interest was 205700 shares in.
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON)'s Trend Unknown, Especially After Increased Shorts - MoneyMakingArticles
Posted: December 3rd, 2018, 2:00pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON)'s Trend Unknown, Especially After Increased Shorts MoneyMakingArticlesThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 11.92% in short interest. TCON's total short interest was 205700 shares in.
-
Low Pressure Mercury Lamps Market Size USD and Forecast by Leading Players upto 2022 - The Future Gadgets
Posted: December 3rd, 2018, 7:51am GMT
Low Pressure Mercury Lamps Market Size USD and Forecast by Leading Players upto 2022 The Future GadgetsCMI released a new market study on 2018-2026 Angiosarcomas Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through ...
-
Angiosarcomas Treatment Market Emerging Trends,Forecasts 2018-2026 And Major Key Companies - Coherent News
Posted: December 3rd, 2018, 11:29pm GMT
Angiosarcomas Treatment Market Emerging Trends,Forecasts 2018-2026 And Major Key Companies Coherent NewsThe Angiosarcomas Treatment Market report released and promoted by CMI draw out historical, existing, and forecast valuation of the Angiosarcomas Treatment ...
-
Why the Angiosarcomas Treatment is a Growing Payer Opportunity? - Coherent Times
Posted: December 1st, 2018, 9:52am GMT
Why the Angiosarcomas Treatment is a Growing Payer Opportunity? Coherent TimesAngiosarcomas Treatment Market report studies the Angiosarcomas Treatment with many aspects of the industry like the market size, market status, market ...
-
Why the Angiosarcomas Treatment is a Growing Payer Opportunity? - Coherent Wire
Posted: November 30th, 2018, 8:25am GMT
Why the Angiosarcomas Treatment is a Growing Payer Opportunity? Coherent WireGlobal Angiosarcomas Treatment Market Analysis, Size, Share, Outlook and Forecast to 2018-2026 is a professional and in-depth research report on the world's ...
-
Sfe Investment Counsel Has Cut Intel (INTC) Stake By $335,062; Tracon Pharmaceuticals (TCON) Shorts Raised By 11.92% - EN Digest
Posted: November 29th, 2018, 2:59pm GMT
Sfe Investment Counsel Has Cut Intel (INTC) Stake By $335,062; Tracon Pharmaceuticals (TCON) Shorts Raised By 11.92% EN DigestTracon Pharmaceuticals Inc (NASDAQ:TCON) had an increase of 11.92% in short interest. TCON's SI was 205,700 shares in November as released by FINRA.
-
Angiosarcomas Treatment Market Headed for Growth and Global Expansion by 2026 - Morgan Newspaper USA
Posted: November 28th, 2018, 6:42pm GMT
Angiosarcomas Treatment Market Headed for Growth and Global Expansion by 2026 Morgan Newspaper USAAngiosarcomas Treatment Market Research Study provides detailed information about the key factors influencing the growth of the industry which include ...
-
Angiosarcomas Treatment Market Top-Vendor Offerings End-User Segments Forecasted Till 2026 - The Industry Chronicle
Posted: November 28th, 2018, 4:38am GMT
Angiosarcomas Treatment Market Top-Vendor Offerings End-User Segments Forecasted Till 2026 The Industry ChronicleCoherent Market Insights Research Report on “Angiosarcomas Treatment Market Study 2018-2026, The report offers a collection of superior market research, ...
-
Cancer, Debt and the Holidays - Curetoday.com
Posted: November 27th, 2018, 7:25pm GMT
Cancer, Debt and the Holidays Curetoday.comBlack Friday Sales this year came and went, and all I did to commemorate the biggest shopping event of the season was delete the masses of emails out of my ...
-
On Prostheses, Corsets and Pineapple Martinis - Curetoday.com
Posted: November 26th, 2018, 3:03pm GMT
On Prostheses, Corsets and Pineapple Martinis Curetoday.comIt's that time of year again to get a new prosthesis for my missing breast, which I lost due to breast cancer. The prosthesis store is 45 minutes away, so I ask my ...
-
Angiosarcomas Treatment Market to Display a Positive Growth With Major Key Players - Coherent Chronicle
Posted: November 24th, 2018, 6:00am GMT
Angiosarcomas Treatment Market to Display a Positive Growth With Major Key Players Coherent ChronicleResearch Expert in Angiosarcomas Treatment has announced new analysis on Angiosarcomas Treatment Market Status 2018-2026 which has been prepared ...
-
Angiosarcomas Treatment Market to Display a Positive Growth With Major Key Players - Coherent Chronicle
Posted: November 24th, 2018, 6:00am GMT
Angiosarcomas Treatment Market to Display a Positive Growth With Major Key Players Coherent ChronicleResearch Expert in Angiosarcomas Treatment has announced new analysis on Angiosarcomas Treatment Market Status 2018-2026 which has been prepared ...
-
Soft Tissue Sarcoma Treatment Market Poised to Incur Steadfast Growth During 2017-2025 - 364Analyze.com
Posted: November 22nd, 2018, 8:54am GMT
Soft Tissue Sarcoma Treatment Market Poised to Incur Steadfast Growth During 2017-2025 364Analyze.comSarcoma are the type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. It occurs in the blood vessels, ...
-
POT1 Revealed as a Sarcoma Predisposition Gene - Cancer Therapy Advisor
Posted: November 17th, 2018, 6:00am GMT
POT1 Revealed as a Sarcoma Predisposition Gene Cancer Therapy AdvisorIn a paper presentation during the Connective Tissue Oncology Society (CTOS) 2018 Annual Meeting in Rome, Italy, Mandy Ballinger, PhD, of the Garvan ...
-
Diagnose This 58-Year-Old Man With Purpuric Nodules - Cancer Network
Posted: November 16th, 2018, 4:26pm GMT
Diagnose This 58-Year-Old Man With Purpuric Nodules Cancer NetworkA 58-year-old man presents with a history of several purpuric nodules on the right leg and foot. What is your diagnosis?
-
Eikenhof mother (39) with rare cancer fighting to stay alive - Comaro Chronicle
Posted: November 16th, 2018, 6:00am GMT
Eikenhof mother (39) with rare cancer fighting to stay alive Comaro ChronicleThe mother of two has been diagnosed with Angiosarcoma cancer in 2015. It is a very rare cancer.
-
Recent Movement: TRACON Pharmaceuticals (NASDAQ: TCON) - Reagents Global Market
Posted: November 16th, 2018, 6:00am GMT
Recent Movement: TRACON Pharmaceuticals (NASDAQ: TCON) Reagents Global MarketThe growth of the EPS is critical in understanding the current valuation of TRACON Pharmaceuticals. It is usually expressed as a percentage and is then ref.
-
Diagnose This 58-Year-Old Man With Purpuric Nodules - Cancer Network
Posted: November 16th, 2018, 6:00am GMT
Diagnose This 58-Year-Old Man With Purpuric Nodules Cancer NetworkA 58-year-old man presents with a history of several purpuric nodules on the right leg and foot. What is your diagnosis?
-
TRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma - GlobeNewswire
Posted: November 15th, 2018, 6:00am GMT
TRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma GlobeNewswireChanges in Endoglin Expressing Circulating Tumor Cells (CTC) Detected in Phase 3 TAPPAS Trial Changes in CTC count may be useful as a prognostic ...
-
Angiosarcomas Treatment Angiosarcomas Treatment Market is forecasted to witness a thriving growth by 2026 - The Industry Chronicle
Posted: November 15th, 2018, 6:00am GMT
Angiosarcomas Treatment Angiosarcomas Treatment Market is forecasted to witness a thriving growth by 2026 The Industry ChronicleThe Angiosarcomas Treatment Market report broadly provides the market share, growth, trends and forecasts for the period 2018-2026. The market size in terms ...
-
Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study - PRNewswire
Posted: November 14th, 2018, 6:00am GMT
Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study PRNewswireHOUSTON, Nov. 14, 2018 /PRNewswire/ -- Precision for Medicine and TRACON Pharmaceuticals (NASDAQ: TCON) announced today the presentation of ...
-
Angiosarcomas Treatment Market Expansion to be Persistent During 2018 2026 - Coherent Wire
Posted: November 13th, 2018, 6:00am GMT
Angiosarcomas Treatment Market Expansion to be Persistent During 2018 2026 Coherent WireGlobal Angiosarcomas Treatment Market Provide Forecast Report 2018 presents an market Industry analysis of the report which researched industry growth, ...
-
Global Orphan Drug Market Outlook 2018 – Growth Drivers, Opportunities - Business News
Posted: November 13th, 2018, 6:00am GMT
Global Orphan Drug Market Outlook 2018 – Growth Drivers, Opportunities Business NewsSummary: A new market study, titled “Worldwide Orphan Drug Market Research Report, Analysis, Overview, Trends 2018” has been featured on ...
-
Angiosarcomas Treatment Market Expansion to be Persistent During 2018 – 2026 - Coherent Wire
Posted: November 13th, 2018, 6:00am GMT
Angiosarcomas Treatment Market Expansion to be Persistent During 2018 – 2026 Coherent WireGlobal Angiosarcomas Treatment Market Provide Forecast Report 2018 presents an market Industry analysis of the report which researched industry growth, ...
-
Angiosarcomas Treatment Market Entry Strategies, Countermeasures of Economic Impact Channels to 2026 - The Industry Chronicle
Posted: November 10th, 2018, 6:00am GMT
Angiosarcomas Treatment Market Entry Strategies, Countermeasures of Economic Impact Channels to 2026 The Industry ChronicleThe Global Angiosarcomas Treatment Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast ...
-
On Nov 10, 2018 Tracon Pharmaceuticals Inc (NASDAQ:TCON) Sellers Increased Their Shorts By 11.92% - The EN Bulletin
Posted: November 10th, 2018, 6:00am GMT
On Nov 10, 2018 Tracon Pharmaceuticals Inc (NASDAQ:TCON) Sellers Increased Their Shorts By 11.92% The EN BulletinTracon Pharmaceuticals Inc (NASDAQ:TCON) had an increase of its shares shorted by 11.92%. In November was issued TCON's total 205700 shares shorted ...
-
Angiosarcomas Treatment Market Expansion to be Persistent During 2018 – 2026 - Morgan Newspaper USA
Posted: November 9th, 2018, 7:21pm GMT
Angiosarcomas Treatment Market Expansion to be Persistent During 2018 – 2026 Morgan Newspaper USAGlobal Angiosarcomas Treatment Market Provide Forecast Report 2018 presents an market Industry analysis of the the report which researched industry growth, ...
-
Angiosarcomas Treatment Market Shows Expected Trend to Guide from 2018-2026 with Growth Analysis - Coherent Wire
Posted: November 9th, 2018, 6:00am GMT
Angiosarcomas Treatment Market Shows Expected Trend to Guide from 2018-2026 with Growth Analysis Coherent WireThe Angiosarcomas Treatment Market report presents the global Angiosarcomas Treatment sales and revenue by companies, regions, type and application and ...
-
Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) - Nasdaq
Posted: November 9th, 2018, 6:00am GMT
Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) Nasdaq(RTTNews.com) - The week that went by saw pot stocks gain big, following the U.S. midterm election results, and resignation of Attorney General Jeff Sessions, ...
-
Targeted Radiation an Option for Difficult-to-Treat Pediatric Liver Cancer - BioSpace
Posted: November 8th, 2018, 6:00am GMT
Targeted Radiation an Option for Difficult-to-Treat Pediatric Liver Cancer BioSpacePublished: Nov 08, 2018 By Mark Terry. Luckily, primary malignant liver tumors in children are rare. They account for only 1 to 2 percent of all childhood cancers.
-
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q3 2018 Results - Earnings Call Transcript - Seeking Alpha
Posted: November 7th, 2018, 6:00am GMT
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q3 2018 Results - Earnings Call Transcript Seeking AlphaTracon Pharmaceuticals Inc. (NASDAQ:TCON) Q3 2018 Earnings Conference Call November 07, 2018 04:30 PM ET Executives Charles Theuer - President, ...
-
Singapore swing: Lonza transfers Tracon Ab to single-use plant - BioProcess Insider
Posted: November 6th, 2018, 6:00am GMT
Singapore swing: Lonza transfers Tracon Ab to single-use plant BioProcess InsiderCDMO Lonza has produced the first 2,000 L batch of Tracon Pharmaceuticals' antibody TRC105 from its Singapore facility after transferring production from the ...
-
Angiosarcomas Treatment Market: We're Entering an Era! - Morgan Newspaper USA
Posted: November 5th, 2018, 11:56am GMT
Angiosarcomas Treatment Market: We're Entering an Era! Morgan Newspaper USACMI published a business reserch report on “Angiosarcomas Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts ...
-
5-year-old diagnosed with rare cancer granted Make-A-Wish trip to San Diego Zoo - WITI FOX 6 Milwaukee
Posted: November 2nd, 2018, 5:00am GMT
5-year-old diagnosed with rare cancer granted Make-A-Wish trip to San Diego Zoo WITI FOX 6 MilwaukeeMILWAUKEE -- A 5-year-old boy diagnosed with a life-threatening disease had his wish granted on Friday, Nov. 2. Isaac Gilbertson is heading to the San Diego ...
-
What Caused Neck Pain in This 73-Year-Old Man? - Cancer Network
Posted: October 20th, 2018, 10:37pm GMT
Cancer Network
What Caused Neck Pain in This 73-Year-Old Man?
Cancer Network
Controversy still exists whether primary angiosarcomas of the thyroid occur, or whether these tumors represent part of the spectrum of anaplastic carcinomas of the thyroid. However, tumors described as angiosarcomas will generally show positive ...
-
Soft Tissue Sarcoma Market Five-Year Growth Outlook of CAGR 8.2% Industry Shapers GlaxoSmithKline, Eli Lilly ... - Digital Journal
Posted: October 18th, 2018, 3:27pm GMT
Soft Tissue Sarcoma Market Five-Year Growth Outlook of CAGR 8.2% Industry Shapers GlaxoSmithKline, Eli Lilly ...
Digital Journal
There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. Currently, there are very few ...
and more » -
Researchers Want Cancer Patients To Share Their Medical Information In Search of Cures - TIME
Posted: October 18th, 2018, 1:59pm GMT
TIME
Researchers Want Cancer Patients To Share Their Medical Information In Search of Cures
TIME
The project is currently building four major databases — for metastatic breast cancer, metastatic prostate cancer, angiosarcoma and gastroesophageal cancer — and people like Doyle have been signing up after learning of the project through social ...
Looking to the future of patient-centered cancer research and treatmentThe Boston Globe
Broad Institute Launches Patient-Partnered Cancer Research Non-Profit OrganizationGenomeWeb
Researchers, cancer patients, and philanthropists launch Count Me In, a new model of patient-partnered research to ...PR Newswire (press release)
all 11 news articles » -
Researchers Want Cancer Patients To Share Their Medical Information In Search of Cures - TIME
Posted: October 18th, 2018, 5:00am GMT
Researchers Want Cancer Patients To Share Their Medical Information In Search of Cures TIMEWith the launch of Count Me In, cancer patients can now send their medical information directly to researchers who are searching for cures.
-
Understanding breast cancer types - KVIA El Paso
Posted: October 3rd, 2018, 5:00am GMT
Understanding breast cancer types KVIA El PasoNot all breast cancers are the same. Understand what type of breast cancer you have and how it differs from other types of breast cancer.
-
Patient-partnered genomics study IDs immunotherapy as potential treatment for rare cancer - Medical Xpress
Posted: September 30th, 2018, 5:00am GMT
Patient-partnered genomics study IDs immunotherapy as potential treatment for rare cancer Medical XpressAngiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with ...
-
Cancer Immunotherapy Conference features latest research on response, resistance, treatment - EurekAlert
Posted: September 30th, 2018, 5:00am GMT
Cancer Immunotherapy Conference features latest research on response, resistance, treatment EurekAlertThe Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3 ...
-
Patient-partnered genomics study IDs immunotherapy as potential treatment for rare cancer - EurekAlert (press release)
Posted: September 30th, 2018, 2:17am GMT
Patient-partnered genomics study IDs immunotherapy as potential treatment for rare cancer
EurekAlert (press release)
NEW YORK -- Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp (HFNS), according to data presented at the ...
-
Soft Tissue Sarcoma Market Springs to CAGR of 8.2% A Glimpse of the Industry with Current Market Trends and ... - Digital Journal
Posted: September 25th, 2018, 8:40am GMT
Daily Industry Reports
Soft Tissue Sarcoma Market Springs to CAGR of 8.2% A Glimpse of the Industry with Current Market Trends and ...
Digital Journal
There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. Currently, there are very few ...
GRN RESEARCH PVT LTD | LinkedInLinkedIn
Global Orthopedic Soft Tissue Repair Devices Market 2018 by Manufacturers, Regions, Type and Application, Forecast ...MarketResearchNest.com
all 136 news articles » -
The businessman 'allergic' to the SUN - Daily Mail
Posted: September 19th, 2018, 5:00am GMT
The businessman 'allergic' to the SUN Daily MailJoshua Barnfather, 30, from Hull, suffers from xeroderma pigmentosum, which means his body cannot repair DNA damage caused by UV light. He also has ...
-
The State of the Soft Tissue Sarcoma Market in 2018 and Beyond with All Major Technology Development, Growing ... - Digital Journal
Posted: September 5th, 2018, 11:30am GMT
The State of the Soft Tissue Sarcoma Market in 2018 and Beyond with All Major Technology Development, Growing ...
Digital Journal
There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. Currently, there are very few ...
and more » -
Bethany Huseman - Dickinson County News
Posted: September 4th, 2018, 6:38pm GMT
Dickinson County News
Bethany Huseman
Dickinson County News
25 after a long battle with angiosarcoma cancer. Bethany was born on Dec. 30, 1981, in Des Moines to parents Peggy A. Gardner and Roger D. Huseman. Bethany attended Spirit Lake High School and graduated in 2000. Bethany was a branch manager for ...
-
This RSS feed URL is deprecated
Posted: August 30th, 2018, 5:00am GMT
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at [https:] -
D&K - Jennifer McCann-Black, 33, angiosarcoma, Pawtucket, RI with Dr. Katie Thornton, Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber 8-21-18 - WEEI
Posted: August 21st, 2018, 5:00am GMT
D&K - Jennifer McCann-Black, 33, angiosarcoma, Pawtucket, RI with Dr. Katie Thornton, Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber 8-21-18 WEEIJen was expecting her first child earlier this year when she began feeling very tired and weak. She was in the 31st week of her pregnancy and thought of nothing ...
-
A love for all seasons - The Athletic
Posted: August 16th, 2018, 3:37pm GMT
The Athletic
A love for all seasons
The Athletic
Chris wasn't diagnosed with angiosarcoma — an extremely rare and aggressive cancer that attacks the lining of the blood vessels — until June, but he began experiencing debilitating pain in his back and later his hip in December. We thought he had a ...
-
A love for all seasons - The Athletic
Posted: August 16th, 2018, 5:00am GMT
A love for all seasons The AthleticWe found out my husband was going to die on June 8, the same day the Warriors beat the Cavs to close out their second straight NBA title. He passed away ...
-
Each Type of Breast Cancer, Explained: Invasive, Non-Invasive, More - Prevention.com
Posted: August 15th, 2018, 5:00am GMT
Each Type of Breast Cancer, Explained: Invasive, Non-Invasive, More Prevention.comNo two cases of breast cancer are alike, and complicating matters is the fact that there are eight different types. Here's everything you need to know about each.
-
lgbt characters mcu primary angiosarcoma of the breast - French Tribune
Posted: August 13th, 2018, 1:03pm GMT
lgbt characters mcu primary angiosarcoma of the breast
French Tribune
The yearly report breaks down the frequency and quality of lgbtq.She refused March's offers of help, and remained quietly seated while he got out their wraps and bags.Lorry clean out of the group I am glad primary angiosarcoma of the breast to have ... -
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
Posted: August 8th, 2018, 5:00am GMT
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2018 Results - Earnings Call Transcript Seeking AlphaTracon Pharmaceuticals (NASDAQ:TCON) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Charles Theuer - President and Chief ...
-
'A new beginning': Patients plant sunflowers to raise awareness about rare cancer - Deseret News
Posted: July 30th, 2018, 5:00am GMT
'A new beginning': Patients plant sunflowers to raise awareness about rare cancer Deseret NewsOn Monday, patients and doctors from the Huntsman Cancer Institute took the day to raise awareness about sarcoma, an incredibly rare, staggeringly brutal ...
-
Shining a Light on Radiation-Associated Angiosarcoma - General Surgery News
Posted: July 23rd, 2018, 5:00am GMT
Shining a Light on Radiation-Associated Angiosarcoma General Surgery NewsAn analysis of data from the Netherlands Cancer Registry is casting a much-needed spotlight on radiation-associated angiosarcoma (RAAS) after primary breast ...
-
New Tricks for Old Drugs: What's Already in the Medicine Cabinet Could be the Next Cancer Treatments - Newsweek
Posted: July 19th, 2018, 5:00am GMT
New Tricks for Old Drugs: What's Already in the Medicine Cabinet Could be the Next Cancer Treatments NewsweekAt a time when drugs can take a decade from discovery to market, and as Big Pharma develops fewer drugs, a growing number of researchers are betting on old ...
-
Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies - P&T Community
Posted: July 4th, 2018, 4:39pm GMT
Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies P&T CommunityThe authors discuss the diagnosis, the role of chemotherapy, and the role of emerging therapies in the treatment of metastatic soft tissue sarcoma.
-
Please help this young beautiful woman beat cancer - Pulse Nigeria
Posted: July 3rd, 2018, 5:00am GMT
Please help this young beautiful woman beat cancer Pulse NigeriaAn unexpected cancer has served as a threat to the dreams of Rachel Nengi Fubara, a 27-year-old lady who hopes to own a successful fashion business.
-
Dog Survives Hemangiosarcoma Clinical Trial - American Veterinarian
Posted: June 22nd, 2018, 5:00am GMT
Dog Survives Hemangiosarcoma Clinical Trial American VeterinarianMeet the first dog to complete a clinical trial aimed at treating hemangiosarcoma.
-
Focusing on You: Phase I Clinical Trials at Sylvester Comprehensive Cancer Center - CBS Miami
Posted: June 12th, 2018, 5:00am GMT
Focusing on You: Phase I Clinical Trials at Sylvester Comprehensive Cancer Center CBS MiamiDr. Breelyn Wilky is an oncologist specializing in sarcomas at Sylvester Comprehensive Cancer Center, part of UHealth, the University of Miami Health System.
-
Oshkosh West High School student graduates early, makes most of time with ailing father - The Oshkosh Northwestern
Posted: June 1st, 2018, 5:00am GMT
Oshkosh West High School student graduates early, makes most of time with ailing father The Oshkosh NorthwesternGenavieve Vaillancourt, 18, knew her father was running out of time, so she worked hard to graduate Oshkosh West High School weeks early.
-
Reader Inquiry: What's The Current Outlook For Tracon Pharmaceuticals? - Seeking Alpha
Posted: May 29th, 2018, 5:00am GMT
Reader Inquiry: What's The Current Outlook For Tracon Pharmaceuticals? Seeking AlphaShares have lost around half of their value since my first article. The main value driver, in my eyes, continues to be data from the phase 2b TRAXAR study. Prio.
-
Breast Cancer, Ellen DeGeneres and Me - Curetoday.com
Posted: May 15th, 2018, 5:00am GMT
Breast Cancer, Ellen DeGeneres and Me Curetoday.comIn 2012, I endured several rounds of radiation for my breast cancer, which was diagnosed in October of 2011. My brother, Mike, bless his heart, drove me to my ...
-
Athenex, Inc. Announces First Quarter 2018 Results Nasdaq:ATNX - GlobeNewswire
Posted: May 14th, 2018, 5:00am GMT
Athenex, Inc. Announces First Quarter 2018 Results Nasdaq:ATNX GlobeNewswireSignificant Clinical Milestones and Record Revenue Mark Strong Start to Fiscal 2018. First Quarter 2018 and Recent Business Highlights: Received Orphan ...
-
A review of soft-tissue sarcomas: translation of biological advances i | CMAR - Dove Medical Press
Posted: May 10th, 2018, 5:00am GMT
A review of soft-tissue sarcomas: translation of biological advances i | CMAR Dove Medical PressA review of soft-tissue sarcomas: translation of biological advances into treatment measures Ngoc T Hoang,* Luis A Acevedo,* Michael J Mann, Bhairavi Tolani ...
-
TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update - GlobeNewswire
Posted: May 9th, 2018, 5:00am GMT
TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswireSAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the ...
-
Angiosarcomas Treatment Market Deep Analysis by Production Overview and Insights 2017 - Coherent Chronicle
Posted: May 3rd, 2018, 5:00am GMT
Angiosarcomas Treatment Market Deep Analysis by Production Overview and Insights 2017 Coherent ChronicleAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
Angiosarcomas Treatment Market Deep Analysis by Production Overview and Insights 2017 - Coherent Chronicle
Posted: May 3rd, 2018, 5:00am GMT
Angiosarcomas Treatment Market Deep Analysis by Production Overview and Insights 2017 Coherent ChronicleAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
Korean pharma firms target rare diseases to enter US market - Korea Biomedical Review
Posted: April 30th, 2018, 5:00am GMT
Korean pharma firms target rare diseases to enter US market Korea Biomedical ReviewDomestic pharmaceutical companies are targeting the U.S. market with rare diseases. In 2017, six locally developed drugs received Orphan Drug Designation ...
-
Oraxol Gets Orphan Drug Designation for Angiosarcoma - Monthly Prescribing Reference
Posted: April 19th, 2018, 5:00am GMT
Oraxol Gets Orphan Drug Designation for Angiosarcoma Monthly Prescribing ReferenceThe Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oraxol (Athenex) for the treatment of angiosarcoma. Oraxol is a novel oral t.
-
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma - GlobeNewswire
Posted: April 19th, 2018, 5:00am GMT
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma GlobeNewswireBUFFALO, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, ...
1
2